Abstract 4354
Background
Patients’ perception of clinical trials in Poland is mostly influenced by mass media. The image of CTs is often biased which may have an impact on recruitment.
Methods
Based on an anonymous 25-item Paper and Pencil Interview (PAPI) survey among 191 hospitalized oncological patients we analyzed knowledge, perception, willingness to participate and future expectations of CTs. Nominal scale: Yes/No/Don’t know, Likert scale of 0-5 points and multiple choice questions were applied.
Results
The majority of respondents were: (1) women: 70,2%, (2) people with secondary education: 57,6%, (3) at the age of 60-69: 41,9%, (4) living in cities over 100k inhabitants: 46,1%. Main findings 49,2% of respondents agreed to be enrolled in CTs; 15,3% refused and 35,4% were not certain. Among the driving factors for “YES” were: chance for a better/constant care - 76,3% and access to additional monitoring - 73,1%. 57,0% of respondents declared altruistic reason. The main reasons for not participating were: concern about toxicity - 62,1%, lack of efficacy - 55,2% and being a “guinea pig” - 41,4%. Among respondents uncertain about participation in CT, the factors of the highest impact on potential enrollment were: terminal phase of the disease/no other option: 68,7%/ 56,7%. The incentive of the family member or friend does not have a significant impact - only 19,4% respondents would follow it. Other findings 55,8%/ 54,7% of respondents do not know about the existence of any legal acts/state institutions that oversee CTs. 60,8% of respondents do not know whether there are independent bioethical committees that approve each CT prior to launch. 64,9% of respondents think that research funded by pharma companies is NOT as reliable as that of independent sources eg. medical universities. 76,2% of respondents think that the current amount of information on CTs is insufficient and 87,2% would like to know more.
Conclusions
The level of knowledge about CTs among patients is insufficient but the willingness to participate is high which is mainly driven by a possibility of a better and constant care. The trust in the pharmaceutical industry should be increased.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
A. Kotowski: Full / Part-time employment: Roche Polska sp z o.o. All other authors have declared no conflicts of interest.
Resources from the same session
2553 - Interim analysis of a phase Ib study of cobimetinib plus atezolizumab in patients with advanced BRAFV600 wild type melanoma progressing on prior anti-PD-L1 therapy
Presenter: Shahneen Sandhu
Session: Poster Display session 3
Resources:
Abstract
2743 - The Impact of Targeted Therapies and Immunotherapy in Melanoma Brain Metastases: a Systematic Review and Meta-Analysis
Presenter: Mario Mandala
Session: Poster Display session 3
Resources:
Abstract
5479 - Intracranial Anti-Tumor Activity in Melanoma Brain Metastases with Encorafenib Plus Binimetinib: A Multicenter, Retrospective Analysis
Presenter: Jose Lutzky
Session: Poster Display session 3
Resources:
Abstract
3560 - Outcomes of Patients with Melanoma Brain Metastases (MBM) Treated with Standard of Care Therapy After Being Excluded from MBM-Specific Clinical Trials
Presenter: Kourtney Holbrook
Session: Poster Display session 3
Resources:
Abstract
3175 - The analysis of current treatment outcomes in melanoma patients with brain metastases
Presenter: Joanna Placzke
Session: Poster Display session 3
Resources:
Abstract
4550 - A multivariate model to define prognostic groups among patients with melanoma brain metastases: a 10-year retrospective cohort study
Presenter: Giacomo Pelizzari
Session: Poster Display session 3
Resources:
Abstract
4191 - The immune landscape of melanoma significantly influences survival in patients with highly mutated tumors.
Presenter: Robert Ferguson
Session: Poster Display session 3
Resources:
Abstract
1625 - Final Results from Phase II of Combination with Canerpaturev (formerly HF10), an Oncolytic Viral Immunotherapy, and Ipilimumab in Unresectable or Metastatic Melanoma in 2nd-or later line treatment
Presenter: Kenji Yokota
Session: Poster Display session 3
Resources:
Abstract
5346 - Evaluating polygenic risk score prediction model for melanoma prognosis
Presenter: Miriam Potrony
Session: Poster Display session 3
Resources:
Abstract
5477 - Impact of sarcopenia in patients with metastatic melanoma treated with immunotherapy
Presenter: Maria Grazia Vitale
Session: Poster Display session 3
Resources:
Abstract